Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study. 2005

Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
Servicio de Oncología Médica, Hospital Clínico Universitario, Paseo de San Vicente, 182, 37007-Salamanca, Spain.

A combination of cisplatin and 5-fluorouracil (PF) is considered the standard induction chemotherapy regimen for squamous cell carcinoma of the head and neck (SCCHN). The present study compares the efficacy and safety of a new combination of cisplatin/docetaxel versus the PF regimen. A total of 83 chemotherapy-naive patients with locally advanced SCCHN were randomised to receive every 21 d (i) docetaxel 85 mg/m2 i.v. on day 1 and cisplatin 40 mg/m2 i.v. on days 1 and 2 (arm A) or (ii) cisplatin 100 mg/m2 i.v. on day 1 followed by 5-fluorouracil 1000 mg/m2 in 24 h continuous infusion for 5 d (arm B). A total of 287 cycles (range 1-3 per patient) were administered. Among 76 patients evaluable for response, the overall response rate in arm A was 70% (complete response (CR) 26%, partial response (PR) 44%) and in arm B 69% (CR 16%, PR 54%), respectively. Median survival in arm A was 7.6 months (95% CI: 5.8-11.1) and 9.9 months (95% CI: 7.4-14.6) for arm B. The most frequent grade 3/4 toxicity in arm A was neutropaenia (34.1%) and diarrhoea (9.8%) versus mucositis (29.3%) and neutropaenia (19.5%) in arm B. Both schedules present a similar efficacy, with different but acceptable toxicity patterns.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976

Related Publications

Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
January 2019, Journal of cancer research and therapeutics,
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
January 2013, European journal of cancer (Oxford, England : 1990),
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
June 2015, International journal of clinical oncology,
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
June 2004, International journal of clinical oncology,
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
February 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
June 2004, International journal of radiation oncology, biology, physics,
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
April 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
November 2013, Clinical oncology (Royal College of Radiologists (Great Britain)),
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
January 2006, Anticancer research,
Emilio Fonseca, and Juan José Grau, and Javier Sastre, and Jesús María García-Gómez, and Antonio Rueda, and Miguel Pastor, and Miguel A Lara, and Marta Navalón, and Alfonso Berrocal, and José Luis Tisaire, and Juan Jesús Cruz
January 2023, In vivo (Athens, Greece),
Copied contents to your clipboard!